Scientists at NCCS are identifying potential biomarkers for breast cancer subtypes using multipronged proteomic and metabolomic approaches. They are analyzing various protein and metabolite changes that occur in the diseased state by comparing tissue, serum and urine samples from breast cancer patients to that of samples collected from normal subjects. This analysis is carried out using a series of analytical methods including protein identification and quantification, metabolomics profiling, statistical analysis and validation processes to arrive at a panel of potential protein and metabolite biomarkers for breast cancer.
This intensive analysis approach has a significant application in identifying novel biomarkers for breast cancer which can help in early diagnosis, prognosis and treatment of the disease using non-invasively collected samples, namely blood, urine, saliva etc. Other extended applications of this research would be in identifying protein changes in drug resistant conditions of cancer and designing presonalized cancer therapy.
- Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers, Journal of Proteomics 132 (2016) 112–130 (Article).
- Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma, Journal of Proteomics (2016) Feb 18. pii: S1874-3919(16)30030-6 (Article).
- Metabolomics and its integration with systems biology, Journal of Proteomics 127 (2015) 73-79 (Article).
- Mass spectrometry-based proteomics in molecular diagnostics: Discovery of biomarkers using tissue culture, BioMed Research International (2013) 783131 (Article).
Technology Readiness: TRL B1/B2
Technology Status: Proprietary Know-how
Technology Availability: Know-how available for co-development and/or sponsored projects.